Clay Eye Competitors

When a five-year-old boy was blinded after a regular eye exam failed to spot a retinal detachment, his father made it his life’s work to help eye care professionals by revolutionising retinal imaging. Optos was founded by Douglas Anderson with the goal to make a patient-friendly device to capture a digital ultra-widefield image of the retina. Today, millions of patients around the world have benefited from optomap® retinal imaging. You will find optomap systems in many independent High Street optometrists, as well as eye clinics at Great Ormond Street Hospital in London and Harvard Medical Center in Massachusetts. Our core products produce high resolution optomap images of 82% or 200◦ of the retina, something no other imaging device is capable of in a single comfortable capture. The most recent innovation from Optos integrates ultra-widefield retinal imaging and image-guided Optical Coherence Tomography (OCT). This combined device facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. More than 1,000 published and ongoing clinical trials as well as thousands of case studies and testimonials show the long-term value of optomap imaging and OCT in diagnosis, treatment planning, and patient engagement. As a division of Nikon Co. Ltd, Japan since 2015, Optos is approaching its 30th anniversary and proud to be recognized as a leading provider of devices to eye care professionals to provide a more complete approach to patient care.

Glooko is a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum. We’re uniquely positioned to be the enterprise partner of choice for healthcare providers seeking to reduce glycemic risk, improve safety, and support overburdened clinical teams with coordinated expertise across both outpatient and inpatient care settings. Our connected care solutions portfolio includes the outpatient Glooko diabetes management platform, Glooko Mobile App for people with diabetes, inpatient EndoTool Glucose Management System, and the Glooko XT remote patient monitoring platform in France. All legitimate Glooko job opportunities are posted on our official careers page. Glooko will never ask candidates to pay for resume services, candidate validation, equipment, training, background checks, or any other hiring-related fees as part of the interview or hiring process. If you receive suspicious outreach claiming to be from Glooko or a Glooko employee, please verify the opportunity through our official careers page before engaging further.

Clarify Health is an outcomes company. We work with health systems on the problem most analytics vendors avoid: finding where the care that is best for patients and the care that sustains the health system have come apart, then closing that gap. Clarify Meridian™ and Clarify Arrival™ are built on the same intelligence layer, drawing on 300 million patient journeys and 5.6 trillion price transparency rates. Meridian sees the opportunity across the network: referral leakage, market share gaps, contract economics, site of service decisions and value-based performance. Arrival acts on it, guiding patients to the care they need and measuring every path on one outcome, a booked in-network appointment. Our forward-deployed teams embed alongside the liaisons, contracting leads and service line leaders who do the work, and our economics are tied to measurable results.